The ZUMA-7 trial showed a significant improvement in efficacy with axi-cel therapy, as compared with second-line standard care, in patients with relapsed or refractory large B-cell lymphoma.

Aims: ZUMA-23 is the first Phase 3, randomized controlled study to evaluate CAR T-cell therapy as a first-line regimen for any cancer and will assess axi-cel versus SOC in patients with high …

Dec 1, 2025 · The goal of this clinical study is to assess whether axicabtagene ciloleucel therapy improves the clinical outcome compared with standard of care second-line therapy in …

May 15, 2025 · ZUMA-12 is a multicenter phase 2 study evaluating axicabtagene ciloleucel (axi-cel) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy as part of first-line …

Dec 8, 2025 · This Viewpoint discusses the recent decision by the US Food and Drug Administration to eliminate Risk Evaluation and Mitigation Strategies requirements for chimeric …

Oct 9, 2025 · An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel Versus Standard of Care Therapy as First-Line …

We are excited to begin enrolling patients in a new clinical trial that will make revolutionary CAR T-cell therapy available to eligible patients as a second-line therapy for relapsed/refractory …

ZUMA-23: An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Eficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line …

Jul 10, 2023 · The CAR T-cell therapy axicabtagene ciloleucel (Yescarta) improved survival for people with large B-cell lymphoma that was not responding to initial treatment or had relapsed …

Dec 28, 2017 · In this multicenter, phase 2 trial, we enrolled 111 patients with diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, or transformed follicular lymphoma who had …